| Lisa Clayton, ST | |
|
1000 Highway 12, Hettinger, ND 58639-7530 | |
| (701) 567-6045 | |
| (701) 567-6361 |
| Full Name | Lisa Clayton |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 1000 Highway 12, Hettinger, North Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922192004 | NPI | - | NPPES |
| 18864 | Other | ND | BLUE CROSS OF NORTH DAKOT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 759 (North Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lisa Clayton, ST 208 Lakeview Dr, Hettinger, ND 58639-9500 Ph: (701) 567-2241 | Lisa Clayton, ST 1000 Highway 12, Hettinger, ND 58639-7530 Ph: (701) 567-6045 |
News Archive
A fender-bender may have saved Douglas Collins' life. A CT scan following the accident discovered Collins, 64, had a brain aneurysm, a weakness in the arterial wall that if ruptured could cause a stroke or death. It was not caused by the accident, but likely could have been a ticking time bomb present for years. The aneurysm was large and previously thought to require open surgery and a lengthy recovery.
Amsterdam Molecular Therapeutics, a leader in human gene therapy, announced today that it has entered into an agreement with Institut Pasteur, Paris, France, and a group of French research institutes (together the "Consortium") to support clinical development of a novel gene therapy to treat Sanfilippo B.
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Researchers assessing the impact of revised guidelines for screening mammography issued by the U.S. Preventive Services Task Force (USPSTF) found evidence that the new recommendations may lead to missed cancers and a decline in screening, according to two studies presented today at the annual meeting of the Radiological Society of North America (RSNA).
› Verified 8 days ago
Kali Jacobson, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Highway 12, Hettinger, ND 58639 Phone: 701-567-4561 | |
Taylor Leigh Williams, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1000 Hwy 12, Hettinger, ND 58639 Phone: 701-567-4561 Fax: 701-567-6369 |